RecruitingRetinal DiseaseAge-Related Macular DegenerationRetinitis Pigmentosa

Stem Cell Ophthalmology Treatment Study II

Eligible age

18+ yrs

Accepts

All genders

Locations

2 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.

Sponsor: MD Stem Cells

✓ Have objective, documented damage to the retina or optic nerve unlikely to improve OR
✓ Have objective, documented damage to the retina or optic nerve that is progressive AND have less than or equal to 20/30 best corrected central visual acuity in one or both eyes AND/OR an abnormal visual field in one or both eyes.
✓ Be at least 3 months post-surgical treatment intended to treat any ophthalmologic disease and stable.
✓ If under current medical therapy ( pharmacologic treatment) for a retinal or optic nerve disease be considered stable on that treatment and unlikely to have visual function improvement ( for example, glaucoma with intraocular pressure stable on topical medications but visual field damage ).
✓ Have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.
✓ Be over the age of 18
✓ Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure.
✓ Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.

✕ Patients who are not capable of an adequate ophthalmologic examination or evaluation to document the pathology.
✕ Patients who are not capable or not willing to undergo follow up eye exams with the principle investigator or their ophthalmologist or optometrist as outlined in the protocol.
✕ Patients who are not capable of providing informed consent.
✕ Patients who may be at significant risk to general health or to the eyes and visual function should they undergo the procedure.

Westport

Coral Springs

Source: ClinicalTrials.gov · NCT03011541 · last updated 2026-06-29